Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:

NCT ID: NCT00020332 Completed - Breast Cancer Clinical Trials

Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Start date: October 2000
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy in treating patients who have locally advanced or metastatic breast cancer.

NCT ID: NCT00020267 Completed - Breast Cancer Clinical Trials

Vaccine Therapy in Treating Patients With Metastatic Cancer

Start date: July 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic cancer that has not responded to previous therapy.

NCT ID: NCT00020176 Completed - Breast Cancer Clinical Trials

Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

Start date: June 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of allogeneic peripheral stem cell transplantation in treating patients who have stage IV breast cancer.

NCT ID: NCT00020098 Completed - Breast Cancer Clinical Trials

Complementary or Alternative Medicine Practices Used by Women at Increased Risk for Breast Cancer

Start date: June 2000
Phase: N/A
Study type: Interventional

RATIONALE: Increasing knowledge about the complementary or alternative medicine practices used by women who are at increased risk for breast cancer may provide useful information for planning breast-cancer-prevention strategies. PURPOSE: Clinical trial to determine how many women who are at increased risk for breast cancer use complementary or alternative medicine.

NCT ID: NCT00019916 Completed - Breast Cancer Clinical Trials

Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer

Start date: June 2000
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. It is not yet known whether combining vaccine therapy with interleukin-2 is effective in treating breast and ovarian cancer. PURPOSE: This randomized phase I/II trial is studying the side effects of vaccine therapy and interleukin-2 and to see how well they work in treating women with stage IV, recurrent, or progressive breast or ovarian cancer.

NCT ID: NCT00019812 Completed - Breast Cancer Clinical Trials

Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2

Start date: August 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to make tumor cells stop dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of trastuzumab plus paclitaxel in treating patients who have metastatic breast cancer that overexpresses HER2.

NCT ID: NCT00019500 Completed - Breast Cancer Clinical Trials

Raloxifene in Preventing Breast Cancer in Premenopausal Women

Start date: December 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of raloxifene may be an effective way to prevent breast cancer in premenopausal women. PURPOSE: Phase II trial to study the effectiveness of raloxifene in preventing invasive breast cancer in premenopausal women.

NCT ID: NCT00019435 Completed - Breast Cancer Clinical Trials

LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors

Start date: May 1998
Phase: Phase 1
Study type: Interventional

RATIONALE: The LMB-9 immunotoxin may be able to locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced solid tumors. PURPOSE: Phase I trial to study the effectiveness of LMB-9 immunotoxin in treating patients who have advanced solid tumors that have not responded to standard therapy.

NCT ID: NCT00019084 Completed - Breast Cancer Clinical Trials

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

Start date: February 1996
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining vaccine therapy with interleukin-2 may be an effective treatment for advanced cancer. PURPOSE: Phase II trial to study the effectiveness of a vaccine made with the patients' white blood cells mixed with tumor proteins in treating patients who have advanced cancer.

NCT ID: NCT00019019 Completed - Breast Cancer Clinical Trials

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

Start date: October 1994
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of carboxyamidotriazole and paclitaxel in treating patients with advanced solid tumors or refractory lymphomas.